Treating Metastatic Colorectal Cancer While Questions Remain Unanswered

摘要: Over the past decade, new cytotoxic and biologic therapies beyond old standard-of-care, biomodulated fluorouracil (5-FU), have become available for treatment of metastatic colorectal cancer (mCRC). The introductions irinotecan (Camptosar), oxaliplatin (Eloxatin), bevacizumab (Avastin) prolonged survival, but optimal use these remains to be determined. Issues remain regarding management toxicities, elderly patients or those with poor performance status, duration front-line therapy. This article reviews recent ongoing studies newer in an effort determine best drugs mCRC. Current data support added either 5-FU/leucovorin alone combination (FOLFOX/bevacizumab) (FOLFIRI/bevacizumab). If is used first-line therapy, should discontinued before development severe neurotoxicity reintroduced replaced on disease progression. Definitive conclusions sequence therapy most effective strategy ameliorate toxicity await results prospective clinical trials.